Background Desmoplastic small round cell tumor (DSRCT) is a very uncommon soft-tissue tumor of children and young adults. It has an aggressive course with generally poor survival. In general the assessment of tumor burden and response has relied upon CT or MRI. However these tumors are often metabolically active and can be evaluated using FDG PET/CT imaging. Objective The purpose of this study was to determine the metabolic activity of desmoplastic small round cell tumors using FDG PET/CT imaging and the potential utility of FDG PET/CT in this disease. Materials and methods Eight patients (seven male, one female; ages 2-20 years, median 11 years) with confirmed DSRCT underwent 82 positron emission tomography/ computed tomography (PET/CT) scans. PET/CT was used for initial staging (seven patients, eight scans), monitoring response to therapy (eight patients, 37 scans) and for surveillance of DSRCT recurrence (six patients, 37 scans).
Introduction
Desmoplastic small round cell tumor (DSRCT) is a member of the small round cell family of soft-tissue sarcomas initially described in 1989 by Gerald and Rosai [1] . DSRCT typically affects adolescents and young adults, with a fourfold incidence in males. The tumors are characterized by the presence of small round blue cells with polyphenotypic differentiation, surrounded by desmoplastic stroma. DSRCT is characterized by a reciprocal translocation between chromosomes 11 and 22 [t(11;22)(p13;q12)], which creates a fusion transcript of the EWS and WT1 genes. The tumors express a variety of histological markers, the most common being desmin, keratins (AE1, AE3 and CAM5.2), vimentin and epithelial membrane antigen [2] . These tumors most frequently arise in the abdomen and pelvic region but also occur in the scalp, sinus cavities, hands and paratesticular region [3] [4] [5] [6] . DSRCT is an aggressive disease and has a propensity to spread within the peritoneum and omentum and metastasize to lymph nodes, lungs and liver [3] . For this reason, the prognosis for DSRCT remains poor, with a mean survival less than 3 years [7] .
Diagnosis and staging of DSRCT has relied heavily upon anatomical imaging [8] . CT and MRI are useful for identifying sites of disease, but they are limited in showing the viability and metabolic activity of tumors. [ 18 F]2-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) combined with CT imaging has been well defined as a useful imaging modality for identifying primary tumors of unknown origin and metastases; it is also used for monitoring tumor response to therapy as well as recurrence in several other pediatric malignancies, including sarcomas [9] [10] [11] . Although FDG PET/CT has been used to assess DSRCT [8, [12] [13] [14] [15] [16] [17] , a definitive role for functional imaging in this disease has not been well-established. In previously reported cases of desmoplastic small round cell tumor, FDG PET/CT has been shown to be a valuable tool for evaluation of disease. In two studies, FDG PET/CT revealed DSRCT metastases that were not detectable by CT alone [15] . In a publication by Rosoff and Bayliff [14] , a pelvic mass that was visible by CT imaging after treatment was no longer FDG-avid, providing valuable additional information about the metabolic state of the tumor not measurable by anatomical imaging. Further complicating matters, because of the rarity of the disease there is no formal staging system for DSRCT. Hayes-Jordan et al. [18] proposed a staging system for DSRCT using the Peritoneal Cancer Index, but this method has not been validated.
We hypothesized that FDG PET/CT imaging could lead to more accurate assessment of DSRCT and could be a useful diagnostic tool for disease staging and evaluation. To test this hypothesis, we retrospectively reviewed of the records of patients with this rare disease who underwent FDG PET/CT scans at our institution.
Materials and methods
To assess the metabolic activity of desmoplastic small round cell tumor and to determine the potential utility of FDG PET/ CT in the management of these patients, we conducted a retrospective study of patients with DSRCT who underwent FDG PET/CT scans from April 2002 until July 2014. Patient records were reviewed for demographic data as well as treatment, imaging, pathology and outcome data. We compared the findings from FDG PET/CT scans with anatomical imaging results to determine the utility of FDG PET/CT in identifying DSRCT lesions, verifying tumor response to therapy, and assessing patient outcome based on the changes in metabolic activity of lesions during therapy.
This study was approved by the St. Jude Children's Research Hospital institutional review board, and data management was in compliance with the Health Insurance Portability and Accountability Act of 1996.
Patients
We identified eight children and young adults treated at St. Jude during the study interval with biopsy-proven DSRCT who underwent FDG PET/CT (Table 1) . Each patient's disease was diagnosed based upon clinical, histological, immunohistochemical and genetic criteria. Seven of the eight tumors were positive for the EWS/WT1 gene rearrangement characteristic of DSRCT. The cohort consisted of 7 males and 1 female ranging 2-20 years of age (median 11 years) at the time of diagnosis. There were 82 scans in total. Seven patients (8 scans) underwent PET/CT scans at the time of initial diagnosis, and 7 patients (37 scans) were studied to assess response to treatment. Six patients (37 scans) were studied to monitor for residual or recurrent disease after treatment. Patients underwent 2-17 scans each (mean 10, median 8). Patient 1 has been described in a previous study [19] . All studies were performed for clinical management as requested by the treating physician.
Imaging studies
Five scans were from outside institutions with varying imaging techniques. For FDG PET/CT studies conducted at St. Jude, 5.5 MBq/kg FDG (maximum 444 MBq) was injected intravenously after either overnight fasting or a minimum of 4 h of fasting for afternoon scans. Blood glucose was found to be normal before FDG injection. Patients were kept in a quiet, dark room after injection and were instructed to relax with their arms at their sides in a recumbent position. Approximately 1 h later, attenuation correction and lesion localization by transmission CT images and PET emission images were acquired using a GE Discovery LS PET/CT system (GE Medical Systems, Waukesha, WI). CT acquisition parameters were: tube rotation 0.8 s, slice thickness 0.5 cm, table speed 1.5 cm/rotation, pitch 1.5:1, 120 kV, 90 mA, with dose modulation. Whole-body PET images were obtained from the top of the skull to the feet for 5 min per bed position in two-dimensional mode. All but one scan included extremities. Scans obtained after July 2011 were acquired on a GE Discovery 690 PET/CT system. Those emission images were acquired in threedimensional mode. Table 1 .
Results

A summary of imaging results is included in
Studies at diagnosis (seven patients, eight scans)
Of the seven patients with desmoplastic small round cell tumor who underwent PET/CT studies, each had abnormal uptake of FDG in tumor foci (patient 8 underwent repeat scanning because the outside study did not include the extremities). At initial staging, six had widespread disease and two had localized disease. Of those with widespread disease, four had abdominal-pelvic involvement only (patients 1, 2, 5, 7) and two had thoracic involvement (patients 3 and 8, mediastinal-hilar in both, pulmonary nodules in one) in addition to abdominal-pelvic disease. Patient 2 also had liver metastases. Of the two patients with localized disease (patients 4 and 6), one had neck disease only and one had orbital involvement only. Patient 2, presented in Fig. 1 , was first scanned at the initiation of chemotherapy and showed marked uptake in four abdominal masses, one pelvic mass and one hepatic metastasis. These tumors were all intensely FDG-avid, with SUV max for each mass ranging 6.3-10.0.
Studies for response to treatment (8 patients, 37 scans)
Eight of the patients with DSRCT underwent PET/CT scans (1-11 scans each) to evaluate response to treatment, including surgery. Six patients had at least one abnormal study during treatment; one, patient 6, had only one study after staging, and it showed no abnormal uptake that could be attributed to residual or recurrent tumor following chemotherapy and surgery. Patient 2 underwent three studies during therapy. These showed progressive decline in uptake (SUV max 10 at diagnosis, 6.5 at 1 month, 3.3 at 3 months, and no detectable tumor uptake at 5 months following resection). Pathological examination of the resected tumor showed evidence of treatment effect, which correlates with the tumor's loss of FDG avidity, as seen in other studies [20, 21] . After resection, anatomical imaging did not distinguish residual disease from postoperative change. PET/CT imaging showed no abnormal uptake while the boy continued chemotherapy and radiation treatment. The patient is clinically free of disease 7.5 years following presentation. Surveillance for disease recurrence (6 patients, 37 scans) Six patients had follow-up PET/CT scans (2-14 each) to assess for recurrent disease up to 5 years after presentation. The studies of patient 7 showed both false-positive and truepositive findings (Fig. 3) . Three studies showed abnormal uptake adjacent to the liver (SUV max 6.2) that was biopsied twice and showed inflammation and necrosis. One of these scans showed abnormal uptake in the left upper thorax (SUV max 7.1); the area was surgically removed and confirmed to represent a lung metastasis. Otherwise, 34 scans in the remaining 6 patients showed no evidence for recurrent tumor, and these patients (1, 2, 4, 5, 6, 8) remain in clinical remission 2-10 years from diagnosis.
Discussion
Our retrospective review showed that FDG PET/CT was useful for demonstrating metabolic activity in seven of eight patients with clinically suspected desmoplastic small round cell tumor. For those seven patients, most tumors were intensely FDG-avid when initially imaged, and this avidity was dramatically reduced or completely resolved in the five patients who eventually reached a clinical remission after surgery. In all five of these patients, no new masses identifiable by FDG PET/CT arose after the initial staging study. Only one DSRCT mass, in patient 6, appeared weakly FDG-avid qualitatively at initial presentation because of its close proximity to cerebral cortex, but SUV max of 6.4 confirmed tumor avidity. Thus baseline assessment of tumor uptake illustrates a metabolic heterogeneity of DSRCT tumors that cannot be seen using other imaging modalities.
Of the three patients who had disease progression, FDG avidity decreased in patient 3 in serial scans, although not as dramatically as in patients who eventually went into remission. Although evidence of necrosis was present on anatomical and metabolic imaging, FDG avidity did persist in these tumors, and new abdominal, pelvic and lymph node foci emerged in the final study of this boy. Patient 7 achieved a short-term metabolic response followed by disease recurrence and disease stabilization after additional cancer-directed therapy.
The uptake of FDG in other soft-tissue sarcomas has been shown to correlate with tumor response to chemotherapy and has even been shown to be a better predictor of histopathological response than change in tumor size [20, [22] [23] [24] . In our study, tumors in four patients that showed reduced FDG uptake in serial PET/CT studies had histological evidence of treatment effect when analyzed after resection. In patients 7 and 8, histopathological analysis revealed that the tumors resected after chemotherapy and after having decreased FDG uptake were less cellular than the original biopsy samples. Analysis of patient 7 also showed that the resected tumor tissue contained more macrophages and had a lower nuclear grade, lower proliferation rate, and increased calcification. These indications of treatment effect are consistent with a loss of FDG avidity after tumors were intensely FDG-avid (SUV max 8.4) at initial staging. These findings suggest that decreased tumor uptake of FDG correlates with therapeutic response as determined by histopathological analysis.
In the four patients (2, 4, 5 and 8) who had FDG-avid tumors initially and reached a clinical remission after surgery, a dramatic decrease in FDG uptake was observed in sequential studies. For example, the SUV max of the supraclavicular mass in patient 4 decreased from 11.7 to 4.6 after 2 months of chemotherapy. There has been no evidence of residual disease or recurrence since surgical resection 6 years ago. All other patients in this group had decreases in tumor FDG avidity prior to surgical resection, with similar clinical outcomes. This could indicate that a prolonged remission is more likely to be achieved if the DSRCT tumors become less FDG-avid in response to therapy prior to resection. Patient 7 had recurrent disease after completion of treatment. FDG PET/CT was used to assist selecting a biopsy site and for restaging. Treatment is ongoing.
Because DSRCT is a very rare disease, the cohort for this retrospective review was quite small. Our series may be somewhat skewed compared with that of Arora et al. [25] in regard to location of disease and patient age. In that study, 62 of 65 patients (95%) had primary abdominal-pelvic involvement and only 3 (5%) had extra-abdominal primary tumor sites, two in bone and one in muscle. In our series, of the seven patients studied prior to therapy, five (71%) had abdominal pelvic disease and two (28%) extra-abdominal primary tumors (orbital, supraclavicular). Only one patient in our series had hepatic involvement (13%) while 43% of the Arora series had hepatic metastases. The mean age of patients described in the Arora series was 19.5 years, and in our series it is 11.3 years. Both studies showed male predominance (80% and 87%, respectively). To more confidently conclude that FDG PET/CT findings can indicate therapeutic response and clinical outcome, more comprehensive studies are needed to determine whether similar trends can be seen in other cases of DSRCT. Our findings are, however, consistent with those of other studies involving FDG PET/CT evaluation of sarcomas that indicate that tumor FDG uptake can be an indicator of prognosis [26, 27] . The Arora et al. [25] study described their experience using FDG PET/CT in the staging and follow-up of 11 patients with DSRCT. In an organ-based analysis using biopsy or serial CT or MRI scans, disease was correctly staged using PET/CT in 225 of 231 (97%) locations (21 areas in each patient). Sensitivity, specificity, and positive and negative predictive values were >96%. Our study largely supports the use of PET/CT for staging and adds documentation of the clinical utility of the technique at follow-up in the management of patients.
Although a lesion-by-lesion analysis of FDG PET/CT findings was not performed, FDG PET/CT scans in our study allowed identification of sites of increased metabolic activity that were not noted during examination of anatomical imaging. These findings included a hepatic focus in one patient's initial study, a bony focus in another patient, and lymph node uptake in the initial study of a third patient. These findings were not confirmed by biopsy, and many were not seen on later scans, so it is difficult to determine their relevancy. However, other reported PET/CT studies of patients with DSRCT have identified lesions not visible by other imaging modalities [12] . In our study, the principal use of FDG PET/CT scans at diagnosis was to provide a baseline assessment of metabolic activity for comparison with studies assessing tumor shrinkage in response to treatment effect. The combination of FDG PET/CT and diagnostic contrast-enhanced CT was used in treatment assessment on an individualized basis.
In studies obtained at our institution after DSRCT resection, PET/CT was particularly useful for assessing the likelihood of tumor recurrence when anatomical imaging findings were inconclusive. In multiple surveillance scans, corresponding anatomical imaging showed areas that might indicate residual or recurrent disease. In each of these cases, the additional information provided by metabolic imaging prevented the misdiagnosis of disease relapse.
There were few false-positive findings. Patient 2 had changes caused by radiation pneumonitis. The perihepatic mass of patient 7 is described in Fig. 3 . False-positive findings are not uncommonly seen in FDG PET/CT studies and have been reported [28, 29] .
Our study has limitations. The patient sample was small and may not be representative of the disease at large. Patient therapy was individualized and thus not uniform. PET/CT scans were obtained as part of the clinical management of patients, possibly more frequently acquired in patients believed to be at higher risk for recurrence. Uptake of FDG between and within tumors was quite variable, potentially limiting the utility of the PET/CT technique, particularly in determining response to therapy in areas of tumor that had low initial metabolic activity.
Conclusion
Our review of children and young adults with desmoplastic small round cell tumors showed that FDG PET/CT scans were a useful complement to anatomical imaging for disease assessment. Although there were a limited number of patients in this retrospective review, the data suggest that FDG PET/CT allowed effective identification of DSRCT lesions and accurately depicted the response of tumors to therapy. Overall, these findings indicate that FDG PET/CT imaging is a valuable supplement to anatomical imaging for DSRCT evaluation, and further multi-institutional studies examining the ability of FDG PET/CT findings to predict prognosis could be valuable for future disease management.
